Daniel Lippis Sells 1,019 Shares of Edwards Lifesciences (NYSE:EW) Stock

Key Points

• VP Daniel Lippis sold 1,019 shares on March 11 at an average price of $85.38 for $87,002, reducing his stake by 2.92% to 33,934 shares valued at about $2.90M.
• Edwards reported quarterly EPS of $0.58 versus $0.62 expected (a miss) while revenue rose 13.3% to $1.57B, and the company set Q1 2026 guidance of $0.70–$0.76; analysts forecast full-year EPS of $2.45.
• The stock carries a consensus rating of Moderate Buy with a $96.14 price target, but short interest surged roughly 56.6% to about 12.38M shares, indicating rising bearish positioning.

Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) VP Daniel Lippis sold 1,019 shares of the business's stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $85.38, for a total value of $87,002.22. Following the transaction, the vice president owned 33,934 shares of the company's stock, valued at $2,897,284.92. This trade represents a 2.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Edwards Lifesciences Stock Performance

Shares of EW traded down $0.70 during trading hours on Wednesday, reaching $85.08. 4,313,490 shares of the company's stock traded hands, compared to its average volume of 4,632,605. Edwards Lifesciences Corporation has a twelve month low of $65.94 and a twelve month high of $87.89. The business's fifty day simple moving average is $82.50 and its two-hundred day simple moving average is $81.52. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. The firm has a market capitalization of $49.42 billion, a price-to-earnings ratio of 46.49, a P/E/G ratio of 2.20 and a beta of 0.93.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.04). The company had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The business's revenue for the quarter was up 13.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. UBS Group reiterated a "neutral" rating and issued a $94.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, February 4th. Evercore restated an "outperform" rating and issued a $94.00 target price on shares of Edwards Lifesciences in a research report on Monday, January 5th. Stifel Nicolaus set a $110.00 price target on Edwards Lifesciences and gave the company a "buy" rating in a research note on Tuesday, January 20th. JPMorgan Chase & Co. upgraded Edwards Lifesciences from a "neutral" rating to an "overweight" rating and lifted their price target for the company from $90.00 to $100.00 in a research report on Thursday, December 18th. Finally, TD Cowen raised Edwards Lifesciences from a "hold" rating to a "buy" rating in a research note on Friday, January 9th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $96.14.

Trending Headlines about Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Brokerages give EW an above-average stance — the stock received an average rating of “Moderate Buy,” which supports investor conviction and can attract demand. Edwards Lifesciences Receives Average Rating of Moderate Buy
• Positive Sentiment: Equity-research / retail-content pieces list EW among medical-instruments stocks with short-term upside (citing product pipeline, AI/technology tailwinds and M&A/innovation themes), which can draw momentum buyers and ETF/sector flows. 5 Medical Instruments Stocks to Buy (Zacks)
• Neutral Sentiment: Management presented at the Leerink Global Healthcare Conference — transcript available; these presentations typically reiterate strategy, product updates and address analyst questions but did not contain headline surprises that would immediately re-rate the stock. Leerink Conference Transcript
• Neutral Sentiment: Management also presented at Barclays’ Global Healthcare Conference (transcript posted). Conference transcripts can provide useful color on valve/TAVR trends and margin cadence but usually drive gradual re-rating rather than same-day spikes. Barclays Conference Transcript
• Negative Sentiment: Short interest rose sharply in February — shorted shares increased ~56.6% to ~12.38M (about 2.1% of shares outstanding) with a short-interest ratio ~2.7 days. That surge in bearish positioning can amplify downward moves and increase selling pressure on headline weakness.

Institutional Trading of Edwards Lifesciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in EW. Norges Bank bought a new stake in Edwards Lifesciences during the fourth quarter worth approximately $803,686,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in shares of Edwards Lifesciences by 111.2% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company's stock valued at $714,006,000 after buying an additional 4,805,819 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Edwards Lifesciences by 278.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company's stock valued at $434,318,000 after buying an additional 4,108,270 shares in the last quarter. Marshall Wace LLP lifted its position in shares of Edwards Lifesciences by 127.5% during the 2nd quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company's stock valued at $539,303,000 after acquiring an additional 3,864,908 shares during the last quarter. Finally, Viking Global Investors LP acquired a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at $238,688,000. 79.46% of the stock is owned by institutional investors and hedge funds.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.